BeOne Medicines (ONC) Cash from Investing Activities (2015 - 2026)

BeOne Medicines (ONC) has reported Cash from Investing Activities for 12 consecutive years, with -$49.4 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Cash from Investing Activities rose 25.9% year-over-year to -$49.4 million in Q2 2026; TTM through Jun 2026 was -$182.5 million, a 56.14% increase from a year earlier, with the FY2025 full-year figure at -$276.2 million, up 49.64% from the prior year.
• Cash from Investing Activities was -$49.4 million for Q2 2026 at BeOne Medicines, down from -$45.5 million in the prior quarter.
• Over five years, Cash from Investing Activities peaked at $658.7 million in Q2 2022 and troughed at -$209.8 million in Q1 2024.
• A 5-year average of $12.1 million and a median of -$49.3 million in 2025 frame the typical range for Cash from Investing Activities.
• Across the five-year window, Cash from Investing Activities surged 1512.96% in 2022 and plunged 263.76% in 2024, its largest moves.
• Over 5 years, Cash from Investing Activities stood at $38.5 million in 2022, then slumped by 262.4% to -$62.6 million in 2023, then tumbled by 49.57% to -$93.6 million in 2024, then soared by 59.05% to -$38.3 million in 2025, then decreased by 28.74% to -$49.4 million in 2026.
• The last three Cash from Investing Activities figures came in at -$49.4 million (Q2 2026), -$45.5 million (Q1 2026), and -$38.3 million (Q4 2025), per Business Quant data.